Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan Rogel Cancer Center
With
American Society of Clinical Oncology
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal according to standard clinical criteria OR receiving concomitant LHRH agonist therapy.
Taking aromatase inhibitor therapy (anastrozole, exemestane, or letrozole) for adjuvant treatment of breast cancer or for chemoprevention for at least 3 weeks and no more than 2 years at the time of enrollment.
Planning to take the same AI therapy for at least 15 weeks.
New or worsening joint pain and/or myalgias since starting the AI therapy.
Completion of surgery (mastectomy or lumpectomy/partial mastectomy) for treatment of breast cancer at least 3 months prior to enrollment.
You may not be if
Metastatic breast cancer.
Planned surgery during the 15-week study period.
Clinically significant laboratory abnormalities.
Use of cannabidiol, THC, or marijuana (oral, inhaled, or topical) within the 6 weeks prior to enrollment.
History of or currently has suicidal ideation or attempted suicide.
History of seizure other than febrile seizures in childhood.
Clareo Health | Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
